Carmen Matei

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Eunice S. Wang, Roger M. Lyons, Sunil Gandhi et al. · Journal of Hematology & Oncology · 2012 · 63 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Results of a Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Low-Grade B-Cell Non-Hodgkin's Lymphoma: An Effective and Minimally Toxic Regimen

Robert Drapkin, Nicholas J. Di Bella, D Faragher et al. · Clinical Lymphoma · 2003 · 19 citations

Medicine, Oncology, Pharmacotherapy +11

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

Roger M. Lyons, Richard A. Larson, Michael A. Kosmo et al. · Blood · 2009 · 12 citations

Medicine, Pharmacology, Pharmacotherapy +15